It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...
Targeting amylin is hoped to preserve muscle ... But the Carmot drug is engineered with “biased signaling” that de-emphasizes pathways that could diminish tolerability and efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback